Venrock Healthcare Capital Par Purchases 8,971 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) major shareholder Venrock Healthcare Capital Par bought 8,971 shares of the business’s stock in a transaction on Wednesday, February 12th. The shares were acquired at an average cost of $11.86 per share, for a total transaction of $106,396.06. Following the purchase, the insider now directly owns 4,044,684 shares in the company, valued at $47,969,952.24. This represents a 0.22 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 14th, Venrock Healthcare Capital Par bought 88,794 shares of Oruka Therapeutics stock. The shares were acquired at an average cost of $11.44 per share, for a total transaction of $1,015,803.36.
• On Monday, February 10th, Venrock Healthcare Capital Par acquired 574 shares of Oruka Therapeutics stock. The stock was purchased at an average cost of $10.90 per share, for a total transaction of $6,256.60.

Oruka Therapeutics Stock Up 6.2 %

Shares of NASDAQ ORKA opened at $10.15 on Friday. The firm has a market cap of $355.24 million, a PE ratio of -1.62 and a beta of 0.77. The stock has a fifty day moving average of $14.29. Oruka Therapeutics, Inc. has a 52-week low of $9.53 and a 52-week high of $53.88.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. purchased a new position in shares of Oruka Therapeutics during the fourth quarter valued at $54,000. AlphaCentric Advisors LLC purchased a new position in shares of Oruka Therapeutics during the fourth quarter valued at $119,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Oruka Therapeutics during the fourth quarter valued at $144,000. Squarepoint Ops LLC purchased a new position in shares of Oruka Therapeutics during the fourth quarter valued at $236,000. Finally, Geode Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the third quarter valued at $343,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on ORKA. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research began coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 price objective on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Oruka Therapeutics has a consensus rating of “Buy” and an average target price of $39.86.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.